Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Mizuho Downgrades Avista to Underperform, Lowers Price Target to $38

Mizuho analyst Anthony Crowdell downgrades Avista (NYSE:AVA) from Neutral to Underperform and lowers the price target from $45 to $38.
byBenzinga Newsdesk
February 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Mizuho analyst Anthony Crowdell downgrades Avista (NYSE:AVA) from Neutral to Underperform and lowers the price target from $45 to $38.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia

By Charles Gross
February 14, 7:36 AM
Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).

VERV